Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15579-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#15579-1-AP, RRID:AB_2737362
- Product name
- CBX2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated CBX2 antibody (Cat. #15579-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer.
Chromobox2 inhibition: a novel activity of alisertib, an aurora A kinase inhibitor.
Roles of the CDCA gene family in breast carcinoma.
CBX2 and EZH2 cooperatively contribute to 5-Fu resistance in gastric cancer by suppressing ferroptosis via trimethylation of H3k27.
CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis.
CBX2 Deletion Suppresses Growth and Metastasis of Colorectal Cancer by Mettl3-p38/ERK MAPK Signalling Pathway.
A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma.
USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition.
Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells.
Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis.
SENP3 and USP7 regulate Polycomb-rixosome interactions and silencing functions.
Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway.
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Sun S, Huang L, Ma Y, Wei Z, Zhu M, Chen M, Ying F, Zhou X, Yang P, Wen Y, Yang Q, Cai L, Zhang Y, Cai J
Cell death & disease 2026 Mar 26;17(1)
Cell death & disease 2026 Mar 26;17(1)
Chromobox2 inhibition: a novel activity of alisertib, an aurora A kinase inhibitor.
Yamamoto TM, Iwanaga R, Woodruff ER, Elder AM, Petkov A, Nurmemmedov E, Eisenmesser E, Reigan P, Bitler BG, Brubaker LW
Molecular cancer therapeutics 2026 Jan 24;
Molecular cancer therapeutics 2026 Jan 24;
Roles of the CDCA gene family in breast carcinoma.
Ding W, Han W, Shi CT, Yao LQ, Liang ZW, Zhou MH, Wang HN
Science progress 2025 Jan-Mar;108(1):368504241312305
Science progress 2025 Jan-Mar;108(1):368504241312305
CBX2 and EZH2 cooperatively contribute to 5-Fu resistance in gastric cancer by suppressing ferroptosis via trimethylation of H3k27.
Zeng M, Li B, Guan Q, Cai H
Cellular signalling 2025 Dec;136:112078
Cellular signalling 2025 Dec;136:112078
CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis.
Wang B, Zhang S, Guo Y, Gao W, Wu H, Wang J, Wang Y, Tang C, Liu L
Oncogene 2025 Apr;44(13):909-926
Oncogene 2025 Apr;44(13):909-926
CBX2 Deletion Suppresses Growth and Metastasis of Colorectal Cancer by Mettl3-p38/ERK MAPK Signalling Pathway.
Sun R, Tu X, Chan S, Wang X, Ji Y, Wang Z, Yu Z, Zuo X, Zhang Q, Chen J, Han Q, Wang M, Zhao H, Zhang H, Chen W
Journal of Cancer 2024;15(8):2123-2136
Journal of Cancer 2024;15(8):2123-2136
A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma.
Wu Q, Li P, Tao X, Lin N, Mao B, Xie X
BMC cancer 2024 Sep 2;24(1):1087
BMC cancer 2024 Sep 2;24(1):1087
USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
Chen J, Shan W, Jia Q, Chen Y, Jiang W, Tian Y, Huang X, Li X, Wang Z, Xia B
Oncogene 2024 Oct;43(43):3170-3183
Oncogene 2024 Oct;43(43):3170-3183
Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition.
He C, Zhou W, Jin X, Zhou H
Heliyon 2023 Oct;9(10):e20650
Heliyon 2023 Oct;9(10):e20650
Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells.
Ma Y, Liu L, Wei Z, Zhu M, Huang L, Wang S, Yi X, Ying F, Zhao S, Cai J, Wang Z, Sun S
Molecular carcinogenesis 2023 Apr;62(4):479-492
Molecular carcinogenesis 2023 Apr;62(4):479-492
Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis.
Meng X, Cao R, Liu X, Fu B, Luo L, Jiang M, Wang K, Liu Y, Zhu Q, Yang C, Zhou L
Oncology letters 2023 Apr;25(4):172
Oncology letters 2023 Apr;25(4):172
SENP3 and USP7 regulate Polycomb-rixosome interactions and silencing functions.
Zhou H, Feng W, Yu J, Shafiq TA, Paulo JA, Zhang J, Luo Z, Gygi SP, Moazed D
Cell reports 2023 Apr 25;42(4):112339
Cell reports 2023 Apr 25;42(4):112339
Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway.
Zheng S, Lv P, Su J, Miao K, Xu H, Li M
American journal of translational research 2019;11(3):1668-1682
American journal of translational research 2019;11(3):1668-1682
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, Yang H, Hao B, Shen YY, Su Y, Cong X, Huang M, Tan M, Ding J, Geng M
Cell 2018 Sep 20;175(1):186-199.e19
Cell 2018 Sep 20;175(1):186-199.e19
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The CBX2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human CBX2. This antibody recognizes human, mouse, rat antigen. The CBX2 antibody has been validated for the following applications: ELISA, WB analysis.
